^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) + CYNK-101 (NK cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
270 Developing placental CD34+-derived natural killer cells with high affinity and cleavage resistant CD16 (CYNK-101) in combination with avelumab for enhanced therapy against PD-L1+ solid tumors
Published date:
11/08/2022
Excerpt:
Here, we evaluated anti-tumor activity of CYNK-101 in combination with Avelumab, an anti-PD-L1 antibody, against PD-L1+ lung, breast, and bladder cancer cell lines....Our results demonstrate that CYNK-101 has enhanced Avelumab-mediated ADCC activity against PD-L1+ tumor cell lines, such as lung, breast, and bladder cancers.
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0270
